Recursion

Hoifung Poon, PhD, formerly General Manager of Microsoft Research, has joined Recursion as the company’s first Chief AI Officer. In 15+ years at Microsoft, he led pioneering work in biomedical AI, multimodal foundation models & causal machine learning – including PubMedBERT, GigaPath & GigaTIME.

We’re headed to the U.S. Science Summit! On July 21, Recursion CEO Najat Khan, PhD, will join @biotechtv.bsky.social's inaugural U.S. Science Summit in Kendall Square for a fireside chat, “Who Will Shape the Future of Medicine?” www.biotechtv.com/us-science-s... #USsciencesummit #biotech #Boston

🤖 Automated labs will be a driving force in the AI drug discovery era. A new story in @sciam.bsky.social looks at how automated labs are adding new speed & efficiency to drug discovery & how Recursion is bringing “industrial scale” to lab automation. www.scientificamerican.com/article/auto...

🎉 We’re on the Shatter List! Recursion has been named to the 2026 Women Tech Council’s Shatter List. This is our 9th year making the list, which recognizes workplaces where talented people want to grow, lead, and build meaningful careers. 👉 Learn more: www.womentechcouncil.com/shatter-list/

🚀A new article in Nature Biotech highlights how next-generation AI companies like Recursion are transforming biology into an engineering discipline. Recursion CEO Najat Khan: “On average, we go from project start to advanced candidate in 17 months.” www.nature.com/articles/s41... @nature.com

Bigger isn't always better.” — Dave Hallett, CSO, Recursion At the @synbiobeta.bsky.social event, Dave joined fellow industry leaders to discuss "Solving the Scale Mismatch Between Cells and Patients in Virtual Biology." How do we better translate cellular insights to patient outcomes using AI?

Recursion will provide business updates and report our first quarter 2026 financial results on Wednesday, May 6, 2026, with an Earnings Call at 8:00 am ET / 6:00 am MT / 1:00 pm BST broadcast on our X, LinkedIn, and YouTube accounts. 👉Learn more: ir.recursion.com/news-release...

⏩ Momentum is building across the #TechBio ecosystem. "After a year of keeping its head down and riding out the bumps, biotech is doing what it’s best at again. Innovating. Making things better.” 🧪💡👇

Last week, we held an event called “An Evening of Hope” in honor of Rare Disease Day. Speakers included rare disease advocates, researchers, patients, and community members who shared their personal stories, breakthroughs, and messages of hope. #raredisease #patients www.youtube.com/shorts/nGOqc...

At Silicon Slopes, Recursion Chief Business Officer Matt Kinn spoke to Nasdaq’s Kristina Ayanian about Recursion’s differentiated approach and strategic advantages. www.youtube.com/watch?v=JfLA...

Recursion welcomed rare disease advocates, physicians, patients, and community members for “An Evening of Hope” last week in SLC. The event highlighted the critical work happening to raise awareness & accelerate new treatments & best support patients and their families who are waiting for a cure.

Recursion announced yesterday that the company will participate in a number of upcoming investor conferences. 👉 Check out the webcasts at ir.recursion.com. #investor #financial #AI #drugdiscovery #TechBio

Recursion CSO Dave Hallett was recently appointed as an AI Champion by the UK government. He’s one of 8 AI Champions and will be representing the life sciences industry, helping to inform, guide, and accelerate AI adoption plans in that space. 👉 Learn more: delivery.ai.gov.uk/48/ #TechBio #AI #UK

See you at #SLAS2026! Two of our AI drug discovery experts are presenting at the SLAS International Conference & Exhibition Feb. 7-11 in Boston - on Industrializing Drug Discovery with ML and Leveraging AI to Map Cellular Morphology Across Imaging Modalities. www.slas.org/events-calen...

A new episode of Google’s podcast #WhereTheInternetLives looks at Recursion's approach to making new medicines – relying on massive proprietary datasets spanning biology, chemistry and patient data; supercomputing; and an end-to-end AI platform. www.youtube.com/watch?v=o-8W... #GoogleDataCenters

Leveraging AI & real-world patient data to accelerate drug discovery. In a recent webinar, Sid Jain and Hayley Donnella of Recursion spoke to Shane Woods at Tempus AI about how patient data is driving the latest advances in AI drug discovery. www.tempus.com/resources/co... #TechBio #data 🧪

Beth Bruckheimer, PhD, VP of Clinical Development, shared details on our positive Phase 1b/2 results from the ongoing TUPELO study of REC-4881 for Familial Adenomatous Polyposis (FAP), which offers new hope for patients. www.youtube.com/watch?v=mv0c...

🚀 Recursion has been laying the foundation for a virtual cell from day one – including massive-scale, proprietary biological & chemical datasets, AI models & one of the industry’s most powerful supercomputers. Learn about our progress & what's next: www.recursion.com/news/since-i... #virtualcell

🚀 The energy & momentum happening around life sciences in London – fueled by innovation and investment in #AI – is undeniable, and it was on full display last week at the Jefferies Global Healthcare Conference & London Life Sciences Week presentations and events. www.youtube.com/shorts/r2iwx...

In a new story in Technology Networks, incoming CEO and President Najat Khan shared insights into the creation of the Microglia Map in partnership with Roche and Genentech and what it could mean for future drug discovery. #neuroscience #microglia #TechBio www.technologynetworks.com/drug-discove...

In a new video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts: “What is one thing you wish your families understood about the work that you do?” For many, it’s all about the patients. #onething #Recursionaut #culture #TechBio #drugdiscovery www.youtube.com/shorts/ougrI...

Presenting REC-102: Preclinical in vivo updates for a potential ENPP1 inhibitor for the treatment of hypophosphatasia (HPP). Results of the study have been published in the Journal of Bone and Mineral Research. 👉 Read the paper: academic.oup.com/jbmr/advance... #HPP #ENPP1 #TechBio

At the inaugural TEDx Tribeca on Dec. 3, Recursion incoming CEO and current Chief R&D Officer and Chief Commercial Officer Najat Khan will present her personal journey merging science and technology to make new medicines and improve the lives of patients. www.ted.com/tedx/events/... #NYC #TED #TEDx

Recursion announced a leadership transition plan to drive the next phase of its growth. Effective Jan. 1st, Chris Gibson, Co-Founder and CEO, will transition to Chairman of the Board, Najat Khan, PhD, Chief R&D and Commercial Officer, will be named CEO and President. ir.recursion.com/news-release...

In our latest Explain the Impact video, we share the inside story of the world's first Microglia Map from Recursion and Roche and Genentech to help unlock new targets in neurodegenerative diseases. #neuroscience #techbio youtube.com/shorts/xvPIQ...

💥 Recursion has achieved a $30 million milestone payment from its partners, Roche and Genentech, following the acceptance of the Microglia Map – a first-of-its-kind whole genome map of the brain’s immune cells. 👉Learn more: www.recursion.com/news/how-a-f... #neuroscience #TechBio

The 3rd episode of TechBio Talks is now live, featuring leading AI investor Nathan Benaich of Air Street Capital with host Chris Gibson discussing the evolving landscape of AI in drug discovery, the biggest trends in Nathan’s new State of AI Report, and more! www.youtube.com/watch?v=MUjT...

What gets you excited? In this video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts to share the “one thing” that most excites them about their work. #OneThing #culture www.youtube.com/shorts/zQDQq...

Today, cofounder & CEO Chris Gibson spoke on the Main Stage at #GITEX to discuss how the convergence of AI, data, & DNA is fundamentally changing the way we discover medicines. As he wrote: “This is more than just a shift in technology — it’s a re-architecting of the scientific process itself."

🎫 Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will join leading experts from healthcare, technology, and public policy for Google Cloud’s Cancer AI Symposium on Oct. 30 at Google NYC, exploring how #AI is currently transforming #cancer care – and what’s to come. 🧪

Inside the AI transformation of drug discovery. On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com #GITEXGlobal #GITEX2025 #TechBio

Maintaining our sense of urgency, because patients are waiting. In a clip from the latest installment in our internal #RXU series – Chief R&D Officer and Chief Commercial Officer Najat Khan talks about the importance of urgency. #TechBio

A recent story in @reuters.com looks at momentum happening in #AI drug discovery, noting that AI adoption across the #pharma industry will lead to “faster and cheaper results” including through reduction in animal testing, a recent push from the #FDA. More: www.reuters.com/business/hea...

“We’re focused on going places that we don’t think other people can.” On 9/8, Chris Gibson & Najat Khan presented at the Morgan Stanley Global Healthcare Conference, addressing macro concerns, platform evolution & what we anticipate from partnership milestones 👉 event.webcasts.com/viewer/event...

A new feature in @financialtimes.com looks at what’s needed for #AI drug discovery to begin delivering on its promises and how the latest #ML breakthroughs paired with over a decade of fit-for-purpose data generation has positioned us for that moment. 👉 www.ft.com/content/9a8a...

🌄 The peak is now the basecamp. A new feature in @pharmaphorum.bsky.social looks at how Recursion has built the necessary foundation & is now accelerating into a new era of AI-led drug discovery, focused on delivering transformative, first-in-class medicines. pharmaphorum.com/deep-dive/ai...

In an interview with Occam, Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan outlines the strategy for building a #TechBio company that’s positioned to win. 👉 Read more: www.occam-global.com/blogs/an-int...

🎉 Daniel Cohen, President of Valence Labs (@valenceai.bsky.social), Recursion’s AI research engine, has been named a “Rising Leader” by Citeline. #TechBio #AI #ML #research #virtualcell 👉Read more: insights.citeline.com/in-vivo/lead...

📣 The inaugural episode of TechBio Talks is now live! Host Najat Khan sits down w/ MIT Distinguished Professor Regina Barzilay for a fascinating conversation about the new AI technologies transforming healthcare. ▪️ Spotify: open.spotify.com/show/2bjoBPs... ▪️ YouTube: youtube.com/playlist?lis...

🔹 Join us in September as Recursion executives present at two upcoming investor conferences: ▪️ Sept. 3: Citi 2025 BioPharma Back to School Conference ▪️ Sept. 8: Morgan Stanley 23rd Annual Global Healthcare Conference 👉 Learn more and tune in here: ir.recursion.com. #investor #IR #IRconference

🎙️ Introducing #TechBio Talks – a new podcast hosted by Chris Gibson & Najat Khan offering candid conversations with the scientists, founders, & investors on the frontlines of #AI drug discovery. Subscribe now: ▪️ Spotify: open.spotify.com/show/2bjoBPs... ▪️ YouTube: www.youtube.com/playlist?lis...

🔹 Delivering breakthroughs, at scale. Last week, Erik Douglas, VP of Product, joined some of the biggest names in tech – including Fei-Fei Li and Geoffrey Hinton – at the #Ai4 conference in Vegas where he provided insights into our AI-driven industrialization of drug discovery and development.

🚀 Expanding access to data to accelerate #AI drug discovery. A new article from @britabelli.bsky.social in Future Medicine AI looks at the critical role open datasets play in driving discoveries & initiatives underway to enable more access. www.fmai-hub.com/how-open-dat... #TechBio #drugdiscovery

An article in BioPharmaTrend highlighted our recent earnings report, including “progress on internal assets REC-1245 (RBM39 degrader) and REC-617 (CDK7 inhibitor), alongside a $7 million milestone payment from Sanofi for a partnered immunology program.” www.biopharmatrend.com/news/recursi...